<code id='162E692624'></code><style id='162E692624'></style>
    • <acronym id='162E692624'></acronym>
      <center id='162E692624'><center id='162E692624'><tfoot id='162E692624'></tfoot></center><abbr id='162E692624'><dir id='162E692624'><tfoot id='162E692624'></tfoot><noframes id='162E692624'>

    • <optgroup id='162E692624'><strike id='162E692624'><sup id='162E692624'></sup></strike><code id='162E692624'></code></optgroup>
        1. <b id='162E692624'><label id='162E692624'><select id='162E692624'><dt id='162E692624'><span id='162E692624'></span></dt></select></label></b><u id='162E692624'></u>
          <i id='162E692624'><strike id='162E692624'><tt id='162E692624'><pre id='162E692624'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:112
          Buildings like hospitals and banks on a web with people operating laptops and phones — health tech coverage from STAT
          Adobe

          For years, the playbook for many companies that wanted to market digital therapeutics was stupid simple: Sell it like a prescription drug.

          But just because it was simple didn’t mean it was going to work.

          advertisement

          The bankruptcy of Pear Therapeutics last year proved that selling software-based treatments like drugs is harder than anticipated. Pear received Food and Drug Administration clearance for its app treating substance use disorders and insomnia but insurers mostly refused to cover the novel treatments. Even after hitting roadblock after roadblock, the company stuck to its original plan and ended up vaporizing over $400 million in investment before finally throwing in the towel.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Startup Neumora takes a novel depression drug to Phase 3
          Startup Neumora takes a novel depression drug to Phase 3

          AdobeNeumora,aprivatelyheldbiotechcompany,ismovingintothefinalphaseoftestingwithanoveltreatmentforde

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          In early work, researchers turn to CRISPR to treat Alzheimer's

          AdobeWhenthegenome-editingtoolCRISPRisthoughtofasapotentialmedicine,thetargetsthatfirstcometomindare